Among the APHINITY samples (n = 969) usable for Amsterdam 80-gene subtyping, patients having Her2 +ve tumors with a single activated Her2 subtype had a greater benefit with the addition of pertuzumab to CT/trastuzumab than any other tumor subtypes. This evidence concerns the gene ERBB2 and neoplasm.